Transgene and Nec Report 100% Three-Year Disease-Free
The updated results represent a population (N=33 efficacy evaluable) dosed at 5.4 mg/kg intravenously once every three weeks with a dose equivalent to or below a dose cap. These data demonstrated rapid and deep responses, with a 36 % confirmed objective response rate (cORR) and 94 % disease control rate (DCR). Median progression‑free survival (mPFS) was 6.2 months, and the 12‑month overall survival (OS) probability was 79 %.
Phase 1 monotherapy data for micvotabart pelidotin (MICVO) in patients with second‑line or later recurrent/metastatic head‑and‑neck squamous cell carcinoma (HNSCC) showed a 36 % confirmed objective response rate (cORR), 94 % disease control rate (DCR), median progression‑free survival of 6.2 months and a 12‑month overall‑survival probability of 79 %. No new safety signals were observed.
Positive data at the first‑in‑class microsomal antibody‑drug conjugate level suggest a potentially new, non‑EGFR‑targeted therapeutic option for patients with recurrent or metastatic HNSCC who have progressed after platinum‑based chemotherapy and anti‑PD‑1 therapy.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Spatial Profiling of the Head and Neck Squamous Cell Carcinoma Microenvironment: Reshaping Our Understanding and Therapeutic Opportunities
- Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer
- Review Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review
- Preclinical models in head and neck squamous cell carcinoma
- CAR-Based Cell Therapy in Head and Neck Cancer: A Comprehensive Review on Clinical Applicability